These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24518498)

  • 21. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.
    Figueroa-Vega N; Díaz A; Adrados M; Alvarez-Escolá C; Paniagua A; Aragonés J; Martín-Pérez E; Leskela S; Moreno-Otero R; González-Amaro R; Marazuela M
    Endocr Relat Cancer; 2010 Dec; 17(4):897-908. PubMed ID: 20696814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical strategy for liver metastases of neuroendocrine tumors.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Nakayama T; Tabata Y; Shichinohe T
    Hepatogastroenterology; 2012 May; 59(115):921-3. PubMed ID: 22024223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
    Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
    J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.
    van Vilsteren FG; Baskin-Bey ES; Nagorney DM; Sanderson SO; Kremers WK; Rosen CB; Gores GJ; Hobday TJ
    Liver Transpl; 2006 Mar; 12(3):448-56. PubMed ID: 16498656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix.
    Abdallah R; Bush SH; Chon HS; Apte SM; Wenham RM; Shahzad MM
    Int J Gynecol Cancer; 2016 Mar; 26(3):553-60. PubMed ID: 26825841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.
    Hentic O; Couvelard A; Rebours V; Zappa M; Dokmak S; Hammel P; Maire F; O'Toole D; Lévy P; Sauvanet A; Ruszniewski P
    Endocr Relat Cancer; 2011 Feb; 18(1):51-9. PubMed ID: 20959440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
    Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
    Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
    Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
    Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
    Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
    Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.
    Strosberg JR; Weber JM; Feldman M; Coppola D; Meredith K; Kvols LK
    J Clin Oncol; 2013 Feb; 31(4):420-5. PubMed ID: 23248248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synchronous resection of primary and liver metastases for neuroendocrine tumors.
    Gaujoux S; Gonen M; Tang L; Klimstra D; Brennan MF; D'Angelica M; Dematteo R; Allen PJ; Jarnagin W; Fong Y
    Ann Surg Oncol; 2012 Dec; 19(13):4270-7. PubMed ID: 22752376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
    Auernhammer CJ; Jauch KW; Hoffmann JN
    Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
    Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
    Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
    PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.